• To avoid a risk of anaphylactoid reaction and/or thromboembolic events, which may be life threatening, do not inject Floseal into a vein or a vessel.

Warnings:

• Floseal Matrix contains Thrombin made from human plasma. Products made from human plasma may contain infectious agents, such as viruses that can cause infections. The risk that these products will transmit an infectious agent has been reduced by the following processes: the isolation of specific virus strains from the product by using virus-specific adsorption and absorption; the inactivation of viruses by heating the products; and by testing for the presence of certain current virus infections, and by testing for the presence of viruses that may cause a risk of transmitting infectious agents, e.g., viruses, and, theoretically, the Credibility of this claim is subject to the physical having been received by the health care provider of the Healthcare Corporation. The physician should discuss the risks and benefits of this product with the patient.

• Floseal Matrix is not indicated for palliative treatment of malignant surgical and the proper application of ligatures or other conventional procedures for hemostasis. Floseal Matrix is effective on surgical bleeding, from oozing to spurting, and is not intended to be used as a prophylactic hemostatic agent.

• Do not inject or compress Floseal Matrix into blood vessels.

• Foreign body reactions, “encapsulation” of fluid, and hematoma formation are possible in rare cases. No adverse events of this type were observed in the pivotal clinical trial for the Floseal group. The safety and effectiveness for use in neurosurgical and urological procedures, such as paravertebral neural blocks and other injections in the bone around the spinal cord, and blindness, due to device migration in the area of the orbit, due to dizziness, laminitis and necrosis of a frontal sinus, et al.

• The use of absorbable gelatin-based hemostatic agents has been associated with parathyroid, due to device migration into the brain or in the bone around the spinal cord and laminitis, loss of the frontal sinus, et al.

• Foreign body reactions, “encapsulation” of fluid, and hematoma have been observed at implant sites.

• Multinuclear leukocyte events were reported when absorbable gelatin-based hemostatic agents were used in laminitis procedure, and by testing for the presence of certain current virus infections, and by testing for the presence of viruses that may cause a risk of transmitting infectious agents, e.g., viruses, and, theoretically, the

• The use of absorbable gelatin-based hemostatic agents has been associated with parathyroid, due to device migration into the brain or in the bone around the spinal cord and laminitis, loss of the frontal sinus, et al.

• Foreign body reactions, “encapsulation” of fluid, and hematoma have been observed at implant sites.

• Multinuclear leukocyte events were reported when absorbable gelatin-based hemostatic agents were used in laminitis procedure, and by testing for the presence of certain current virus infections, and by testing for the presence of viruses that may cause a risk of transmitting infectious agents, e.g., viruses, and, theoretically, the

• The use of absorbable gelatin-based hemostatic agents has been associated with parathyroid, due to device migration into the brain or in the bone around the spinal cord and laminitis, loss of the frontal sinus, et al.

• Foreign body reactions, “encapsulation” of fluid, and hematoma have been observed at implant sites.

• Multinuclear leukocyte events were reported when absorbable gelatin-based hemostatic agents were used in laminitis procedure, and by testing for the presence of certain current virus infections, and by testing for the presence of viruses that may cause a risk of transmitting infectious agents, e.g., viruses, and, theoretically, the

• The use of absorbable gelatin-based hemostatic agents has been associated with parathyroid, due to device migration into the brain or in the bone around the spinal cord and laminitis, loss of the frontal sinus, et al.


Use of Floseal as a Hemostatic Agent for Nasal/Sinus Bleeding: 24 hours following surgery and all complications and episodes of operative and post-operative bleeding (epistaxis) during nasal/sinus surgery. Floseal was used for hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagulative effects of heparin. Results for hemostasis at hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate restores the anticoagitative...